Zobrazeno 1 - 10
of 559
pro vyhledávání: '"Burdaeva O"'
Autor:
Glaspy J; UCLA School of Medicine, UCLA Medical Plaza, 100Suite 550, Los Angeles, CA, 90095-6956, USA. jglaspy@mednet.ucla.edu., Bondarenko I; Oncology and Medical Radiology Dept, Dnepropetrovsk Medical Academy, Dnepropetrovsk, Ukraine., Burdaeva O; Arkhangelsk Regional Clinical Hospital, Arkhangelsk, Russia., Chen J; Evive Biotechnology (Shanghai) Ltd, Shanghai, China., Rutty D; Everest Clinical Research, Markham, ON, Canada., Li R; Evive Biotechnology (Shanghai) Ltd, Shanghai, China., Wang S; Evive Biotechnology (Shanghai) Ltd, Shanghai, China., Hou Q; Evive Biotechnology (Shanghai) Ltd, Shanghai, China., Li S; Evive Biotechnology (Shanghai) Ltd, Shanghai, China.
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2023 Dec 16; Vol. 32 (1), pp. 34. Date of Electronic Publication: 2023 Dec 16.
Autor:
Neven P, Johnston S, Toi M, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman P, Koh H, Grischke E, Conte P, Lu Y, Haddad N, Hurt K, Llombart-Cussac A, Sledge G
Publikováno v:
CLINICAL CANCER RESEARCH
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Purpose: In MONARCH 2, abemaciclib plus fulvestrant significantly prolonged progression- free survival (PFS) and overall survival (OS) versus placebo plus fulvestrant in patients with hormone receptor positive (HR+), HER2(-) advanced breast cancer. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::1a95a1d1d0ed43b0f6dab0809ac5347a
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12668
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12668
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kaplanov, K. D., ÖZCAN, MEHMET ALİ, Udovitsa, D. P., Ilyin, N., Alekseev, S. M., Fadjari, H., Arumugan, V., Chakrabarti, P., Kirushnakumar, K. S., Attili, A. V. S. Suresh, Dantas da Cunha Junior, A., Schmidt Filho, J., Franke, F. A., Sampaio Tavares, R., Pinto Simoes, B., Miguel, C. E., Meton, F., Boquimpani, C., Schaffel, R., Cigno, E. L., Basso, A. C., Jarchum, G., Heller, V. B., Bullorsky, E., Furque, M. L., Jones, L., Bassa, F., Osmanov, D. S., Burdaeva, O. N., Melnichenko, V. Y., Uy, N. A., Keat, C. Teng, Rosales, J. D., Galvez, K., Lazaretti, N., Debiasi, M., Santi, P. Xavier, de Mattos, E. R., Luiz da Silva, R., Rodrigues de Oliveira, J. S., Pereira, J., Salvino de Araujo, A., Fogliatto, L., Beguelin, G. Z., Saslavsky, M. M., Munoz, M., Avila, G. I., Moiseevich, M. G., Viktorovich, P. A., Tiangco, B. J., Molina Barrios, G. R., Martinez-Lapus, F. G. P., Villegas, E. M., Raman, R., Gin, G. Gin, Bermudez, C., Ciliao Munhoz, E., Garcia, J. J., De Stefano, G., Caffaro, J., Syafei, S., da Silva Araujo, S. Shusterschitz, Kowalyszyn, R. D., Jasuja, S., Bhurani, D., Radhakrishnan, V., Salvatierra, A., Mukhopadhyay, A., Bhattacharyya, S., Bhatt, N., Perez Diaz, Luis, Paravisini, Alexandra, Fogliatto, Laura, Nodehi, Sayyed Reza Safaee, Patel, Moosa, Volodicheva, Elena Mikhailovna, Lipatov, Oleg Nikolaevich, Guan, Toh See, Querol, John, Flores, David Hugo, Dasappa, Lokanatha, Beniwal, Surender Kumar, Bar, Daniel Oscar, Delamain, Marcia Torresan, Gonzalez, Derlis E., Candelaria, Myrna, Florez, A., Michiels, S., Leao, D., Loggetto, S. R., Szpak, W., Lifirenko, I. D., Ponomarev, R. S., Lysenko, I. B., Vladimirov, V.
Publikováno v:
Leukemialymphoma. 60(14)
This multicenter, double-blind, randomized study compared the efficacy, pharmacokinetics (PKs)/pharmacodynamics (PDs), safety and immunogenicity profile of RTXM83 vs. reference rituximab (R-rituximab), both with CHOP, as first-line treatment of diffu
Autor:
Neven P; Universitaire Ziekenhuizen Leuven, Leuven, Belgium., Johnston SRD; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Toi M; Graduate School of Medicine, Kyoto University, Kyoto, Japan., Sohn J; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea., Inoue K; Saitama Cancer Center, Saitama, Japan., Pivot X; Center Paul Strauss, Inserm U110, Strasbourg, France., Burdaeva O; Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russia., Okera M; Adelaide Cancer Centre, Adelaide, Australia., Masuda N; National Hospital Organization, Osaka National Hospital, Osaka, Japan., Kaufman PA; University of Vermont Cancer Center, Burlington, Vermont., Koh H; Kaiser Permanente, Bellflower, California., Grischke EM; Universitäts-Frauenklinik Tübingen, Eberhard Karls University, Tübingen, Germany., Conte P; DiSCOG University of Padova and Medical Oncology 2, Istituto Oncologico Veneto, I.R.C.C.S., Padova, Italy., Lu Y; Eli Lilly and Company, Indianapolis, Indiana., Haddad N; Eli Lilly and Company, Indianapolis, Indiana., Hurt KC; Eli Lilly and Company, Indianapolis, Indiana., Llombart-Cussac A; Hospital Arnau de Vilanova, Valencia, Spain., Sledge GW; Stanford University School of Medicine, Stanford, California. gsledge@stanford.edu.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Nov 01; Vol. 27 (21), pp. 5801-5809. Date of Electronic Publication: 2021 Aug 10.
Autor:
Zhang, Qingyuan1 (AUTHOR), Wang, Zhonghua2 (AUTHOR), Yao, Wei3 (AUTHOR), Wang, Shufang3 (AUTHOR), Zhang, Gaochong3 (AUTHOR), Chen, Jianmin3 (AUTHOR), Hou, Qingsong3 (AUTHOR), Li, Simon3 (AUTHOR), Li, Hongsheng4 (AUTHOR), Ye, Changsheng5 (AUTHOR), Sun, Tao6 (AUTHOR), Yang, Hongjian7 (AUTHOR), Chen, Zhendong8 (AUTHOR), Wang, Zhihong9 (AUTHOR), Liu, Xiaoan10 (AUTHOR), Geng, Cuizhi11 (AUTHOR), Li, Xingrui12 (AUTHOR), Zhang, Jin13 (AUTHOR), Zheng, Hong14 (AUTHOR), Shao, Zhimin2 (AUTHOR) zhimingshao@fudan.edu.cn
Publikováno v:
BMC Cancer. 9/13/2024, Vol. 24 Issue 1, p1-10. 10p.
Autor:
Perez, Aleymi M.1,2 (AUTHOR) aperez31980@med.lecom.edu, Haberland, Nicole I.1,3 (AUTHOR) ni315488@ucf.edu, Miteva, Mariya1 (AUTHOR) mmiteva@med.miami.edu, Wikramanayake, Tongyu C.1,4 (AUTHOR) tcao@med.miami.edu
Publikováno v:
Current Oncology. Sep2024, Vol. 31 Issue 9, p5709-5721. 13p.
Autor:
Awada, Ahmad1 (AUTHOR) ahmadawada21@gmail.com, Ahmad, Sarfraz1 (AUTHOR) ahmadawada21@gmail.com
Publikováno v:
Current Oncology. Sep2024, Vol. 31 Issue 9, p5374-5383. 10p.
Autor:
Püsküllüoğlu, Miroslawa1 (AUTHOR) agnieszka.rudzinska@krakow.nio.gov.pl, Ziobro, Marek1 (AUTHOR) tomasz.zemelka@krakow.nio.gov.pl, Lompart, Joanna1 (AUTHOR) aleksandra.grela-wojewoda@krakow.nio.gov.pl, Rudzińska, Agnieszka1 (AUTHOR), Zemełka, Tomasz1 (AUTHOR), Jaworska, Justyna1 (AUTHOR), Ochenduszko, Sebastian2 (AUTHOR) sebaochenduszko@gmail.com, Grela-Wojewoda, Aleksandra1 (AUTHOR)
Publikováno v:
Cancers. Aug2024, Vol. 16 Issue 16, p2894. 17p.